Dexcom Inc. executives may have thought a $30 million beat of the consensus estimates for third quarter revenue and 20% growth year-over-year provided a treat to shareholders, but investors seemed to ...

After dealing with a deployment problem with glucose monitors earlier this year, interim CEO Jake Leach said improving ...

DexCom may be a major player in the market for continuous glucose monitors, but that doesn’t means it’s shielded from ...

Amid some scrutiny over its latest-generation G7 CGM, Dexcom officials addressed claims on the company's latest earnings call ...

By Sneha S K (Reuters) -Dexcom shares tumbled 12.8% on Friday after executives signaled that the medical device maker's 2026 ...

Medical device company DexCom (NASDAQ:DXCM) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales ...

As people around the world seek ways to manage their diabetes, the continuous glucose monitor (CGM) market continues to grow ...

Medical device maker Dexcom topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring systems.

Scan, the smart-health device that analyzes your urine from inside your toilet bowl, is finally available to order globally.

Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q3 CY2025, with sales up 21.6% year on ...

DexCom's stock could drop even more if results falls short of revenue expectations. Whatever happens on Oct. 30, the medical ...

RBC Capital is particularly bullish on Insulet. Investor sentiment is positive ahead of the company’s Q3 earnings report ...